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Abstract: Neovascular age-related macular degeneration (AMD) is a visually devastating condition 
resulting from choroidal neovascularization and secondary photoreceptor loss. Ranibizumab and 
bevacizumab are medications that target vascular endothelial growth factor (VEGF). While other 
therapies have demonstrated some ability to reduce the risk of losing vision from neovascular AMD, 
most patients continue to lose some degree of central visual acuity. There is growing evidence that 
intravitreal administration of ranibizumab and bevacizumab is effective in signiﬁ  cantly improving 
the visual acuity in patients with neovascular age-related macular degeneration.
Keywords: age-related macular degeneration, choroidal neovascularization, ranibizumab, 
bevacizumab.
Introduction
Age-related macular degeneration (AMD) is a common condition affecting the central 
vision of older adults. It has been estimated to occur in approximately 25% (Klein et al 
1992) of individuals over the age of 65.  AMD usually begins with degenerative changes 
to Bruch’s membrane and the retinal pigment epithelium (RPE) in the central retina 
(macula), resulting in mild to moderate atrophy and dysfunction of the overlying 
neurosensory retina often referred to as dry AMD. 
Approximately 25% (AED 2001) of AMD patients will develop severe vision loss 
from either geographic atrophy or choroidal neovascularization (CNV), commonly 
known as wet or neovascular AMD. CNV represents angiogenesis from the choroid 
into the sub-RPE or sub-retinal space and commonly results in profound central visual 
loss as photoreceptors are damaged then destroyed by exudation leading to intraretinal/
subretinal/subRPE ﬂ  uid, hemorrhage, and eventual ﬁ  brotic scarring (Figures 1–4). 
CNV have been classiﬁ  ed into either classic or occult types based on vascular leakage 
characteristics on ﬂ  uorescein angiography. These angiographically-deﬁ  ned types may 
be related to whether the neovascularization is anatomically located in the subretinal or 
sub-RPE space, respectively (SST 2006). 
Choroidal neovascularization development involves inﬂ  ammation, angiogenesis, 
and, eventually, ﬁ  brosis. Vascular endothelial growth factor (VEGF) has been recog-
nized as one important contributor (Kvanta et al 1996) in the complex and incompletely 
elucidated mechanisms of CNV development.
Current treatment of AMD
Antioxidant vitamin supplementation (AED 2001) has been found to beneﬁ  t patients 
with high risk dry AMD, reducing the risk of visual loss by approximately 30% over 
6 years. Treatment is aimed at arresting further atrophic changes of the RPE and the 
prevention of CNV.
Once individuals have developed neovascular AMD, therapies are employed which 
target obliteration or regression of neovascularization. Currently available and approved 
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treatments for neovascular AMD include: focal thermal laser; 
photodynamic therapy with verteporﬁ  n (Visudyne, QLT Photo-
therapeutics, Inc., Vancouver, British Columbia); and targeted 
anti-VEGF treatment with pegaptanib (Macugen, Eyetech 
Pharmaceuticals, New York, NY) and the recently US Food 
and Drug Administration-approved ranibizumab (RhuFab 
V2, Lucentis, Genentech, Inc., South San Francisco, CA).
Focal thermal laser may be used to photocoagulate CNV, 
but treatment is reserved for lesions not involving the center 
of the macula (fovea) as such treatment results in an immedi-
ate loss of central vision (MPSG 1991). Treatment does not 
prevent recurrent CNV formation. For CNV involving the 
fovea, a number of treatments have been shown to reduce the 
risk of central visual loss. Several treatment options are brieﬂ  y 
described below. 
Photodynamic therapy (PDT) uses the photoactive intra-
venous medication, verteporﬁ  n, which localizes preferentially 
to neovascularization. Once activated by nonthermal laser, 
verteporﬁ  n results in free radical production and subsequent 
damage to the neovascular tissue targeted. PDT has been shown 
to reduce visual loss in those individuals with small or predomi-
nantly classic subfoveal CNV (TAP 2001, 2003). However, 
most patients require multiple retreatments and collateral 
damage to adjacent healthy tissues may occur with resultant 
reduction in visual function (Reinke et al 1999).
Pegaptanib is an RNA oligonucleotide with afﬁ  nity and 
speciﬁ  city for the VEGF 165 amino acid isoform, the isoform 
thought to play the dominant role in pathologic neovasculari-
zation (Ishida et al 2003; McColm et al 2004). Given as an 
intravitreal injection every 6 weeks, it has been shown to 
signiﬁ  cantly reduce visual loss in patients with CNV regard-
less of type or size (Gragoudas et al 2004). 
In addition to the above approved therapies, other treatments 
are currently undergoing further evaluation. Corticosteroids 
Figure 1 Color fundus photograph of a normal left eye.Clinical Interventions in Aging 2006:1(4) 453
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possess anti-inﬂ  ammatory and anti-angiogenic properties (Danis 
et al 1996; Ciulla et al 2001) and reduce vascular permeability 
(Penfold et al 2000). Early case series of treatment combining 
intravitreal steroids with PDT have demonstrated promise 
(Spaide et al 2003) and larger, prospective, randomized studies 
are currently underway to determine whether such combination 
treatment may result in better visual outcomes than with PDT 
alone. However, intra- or peri-ocular corticosteroid use may 
be limited by induced glaucoma and cataracts in a signiﬁ  cant 
number of patients (Smithen et al 2004). 
Anecortave acetate is a cortisene molecule, speciﬁ  cally 
designed to retain the anti-angiogenic properties of corticos-
teroids while eliminating the aforementioned side-effects and 
is administered as a posterior juxtascleral depot injection every 
6 months (Figure 5) (AAC 2003). A recent study comparing 
anecortave acetate with PDT for the treatment of CNV found 
that it did not meet the speciﬁ  ed noninferiority criteria (Slakter 
et al 2006). 
Surgical removal of CNV in AMD has been studied in a 
randomized, controlled trial and was found not to be better 
than observation alone with regards to maintenance of vision 
(SST 2004a, 2004b).
Ranibizumab
Treatment rationale and principles
VEGF is an important mediator of angiogenesis, playing a 
major role in endothelial cell proliferation and migration, and 
greatly increases vascular permeability. It exists as multiple 
isoforms with VEGF-165 the most pathogenic. VEGF acts as 
the ligand for 2 endothelial cell membrane-bound receptors, 
VEGFR-1 and VEGFR-2, with the latter being the mediator 
for angiogenesis (Robinson and Stringer 2001). 
Figure 2 Color fundus photograph of a right eye with central geographic atrophy. Note the central RPE pigment attenuation.
Abbreviations:  RPE, retinal pigment epithelium.Clinical Interventions in Aging 2006:1(4) 454
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Levels of VEGF are found to be elevated in those 
individuals with proliferative diabetic retinopathy (Adamis 
et al 1994), ischemic central retinal vein occlusion (Aiello 
et al 1994), and CNV (Kvanta et al 1996). Further, experimentally 
increased expression of VEGF has been shown to be sufﬁ  cient to 
induce neovascularization in primates (Tolentino et al 1996). 
A potential strategy in the treatment of neovascular AMD 
would therefore be to inhibit the action of VEGF to inhibit or 
cause regression of vision-threatening CNV while also reduc-
ing intraretinal and subretinal ﬂ  uid accumulation by reducing 
vascular permeability associated with VEGF activity.
Introduction of monoclonal antibodies to VEGF have been 
shown to inhibit development of ocular neovascularization in 
primates (Adamis et al 1996) and anti-angiogenic agents have 
been shown to increase vessel closure in combination with PDT 
in cultured retinal capillary endothelial cells (Renno et al 2000).
At present, only three anti-VEGF agents have been 
approved for use in humans. Pegaptanib and ranibizumab for 
neovascular AMD (see above) and bevacizumab (Avastin, 
Genentech, Inc., South San Francisco, CA), a recombinant, 
monoclonal antibody to VEGF, approved for treatment of 
metastatic colorectal cancer (Hurwitz et al 2004).
Ranibizumab (RhuFab V2, Lucentis, Genentech, Inc., 
South San Francisco, CA) is a 48 kDA, recombinant, 
humanized, monoclonal antibody fragment (Fab portion) 
derivative of bevacizumab with speciﬁ  city to all isoforms 
of VEGF and is designed to inhibit angiogenesis and reduce 
vascular permeability in neovascular AMD. Given as an 
intravitreal injection (Figure 6), it has been designed with 
the theoretical advantage over whole IgG antibodies of being 
able to better cross the internal limiting membrane and thus 
gain better access to CNV in the subretinal space (Mordenti 
et al 1999; Gaudreault et al 2005).
Animal studies
When given as a bilateral 500μg or 2000μg intravitreal 
injection to monkeys (Guadreault et al 20005), ranibi-
zumab distributes quickly to the retinal tissues with 
Figure 3a Color fundus photograph of left subfoveal choroidal neovascularization demonstrating subretinal ﬂ  uid, intraretinal lipid exudate, and subretinal hemorrhage.Clinical Interventions in Aging 2006:1(4) 455
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peak concentrations being found at 6 hours and 1 day, 
respectively, and a terminal half-life of 2.6 days. Concen-
trations of ranibizumab in the neurosensory retina were 
approximately two times greater than in the RPE/Bruch’s 
membrane complex, with both being greater than 1000-
fold the concentration of VEGF normally detected in the 
retina. Maximum serum concentrations were detected 6 
hours following administration of either dose and serum 
half-life was approximately 3.5 days. Maximum serum 
concentrations were found to be low, with 150 ng/mL and 
616 ng/mL detected in the lower and higher dose groups, 
respectively. No antibody production to ranibizumab was 
detected up to 11 days post-injection.
Intravitreal ranibizumab given every two weeks has been 
studied in the laser-induced model of CNV in monkeys. Sig-
niﬁ  cant prevention of CNV formation in susceptible animals 
and reduction of CNV activity expressed as angiographic 
leakage in those animals already harboring neovascularization 
was found (Krzystolik et al 2002). All study eyes developed 
transient intraocular inﬂ  ammation which resolved over 1 week 
and became less pronounced with subsequent injections. 
In a similar study of laser-induced CNV in cynomolgus 
monkeys, intravitreal ranibizumab plus PDT (each given 
every 2 weeks) was found to result in fewer subjects with 
angiographic leakage compared to PDT alone, although this 
result was not statistically signiﬁ  cant given the small sample 
size (Husain et al 2005). Of 12 eyes receiving ranibizumab 
plus PDT, none had angiographic leakage 42 days following 
treatment, whereas 2 of 12 eyes receiving only PDT demon-
strated persistent leakage. Histopathological specimens in the 
combination group demonstrated no patent vessels in the area 
of the CNV. Specimens in the PDT-only group showed rare 
open vessels. No other architectural differences were noted 
between the 2 groups.
Figure 3b Early arteriovenous phase ﬂ  uorescein angiogram demonstrating early central hyperﬂ  uorescence of the choroidal neovascularization. Note blockage of ﬂ  uores-
cence by hemorrhage and relative lack of ﬂ  uorescence in surrounding subretinal ﬂ  uid.Clinical Interventions in Aging 2006:1(4) 456
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Human studies
In humans, ranibizumab was well tolerated in single intravitreal 
doses to 500μg in a study involving 27 subjects with doses 
ranging from 150–1000μg. Signiﬁ  cant intraocular inﬂ  am-
mation was found in the 2 subjects given a ranibizumab dose 
of 1000μg (Rosenfeld, Schwartz, et al 2005). Some degree 
of ocular inﬂ  ammation was seen in 44% of subjects with 
all but 3 of 27 (including the 2 subjects in the 1000μg dose 
group) experiencing only mild, transient inﬂ  ammation. 78% 
of patients experienced some mild, self-limited adverse events 
(eg, subconjunctival hemorrhage, conjunctival edema, or pain) 
related to the injection itself but not the medication.
There are currently 2 large phase III trials, MARINA and 
ANCHOR, evaluating the efﬁ  cacy in treating neovascular 
AMD with ranibizumab over a 24 month period. Both of 
these pivotal studies have been published recently. Their 
results are summarized below (Brown et al 2006; Rosenfeld 
et al 2006).
The MARINA (Minimally classic/occult trial of Anti-VEGF 
antibody RhuFab V2 In the treatment of Neovascular AMD) Trial 
prospectively randomized 716 patients 1:1:1 to receive monthly 
intravitreal ranibizumab (300μg or 500μg) or sham injections for 
24 months. At inclusion, subjects had ﬂ  uorescein angiographic 
evidence of subfoveal minimally classic or occult with no classic
CNV secondary to AMD and no prior history of PDT 
treatment.
At 24 months, 91% of subjects in the ranibizumab groups 
maintained or improved vision (deﬁ  ned as a loss of fewer than 
15 ETDRS letters in visual acuity) compared with 53% of subjects 
in the control/sham group (p < 0.0001) (Heier 2006). 26% of 
subjects receiving 300μg of ranibizumab and 33% of those 
receiving 500μg gained at least 15 letters of vision compared 
with 4% in the control group (p < 0.0001). On average, sub-
jects in the ranibizumab group gained 5.4 and 6.6 letters of 
visual acuity in the 300μg and 500μg groups, respectively, 
while those in the control group lost 14.9 letters (Figure 7).
Figure 3c Late phase ﬂ  uorescein angiogram with late leakage of the choroidal neovascularization (predominantly classic type).Clinical Interventions in Aging 2006:1(4) 457
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Ocular side effects were uncommon in the ranibizumab 
group: endophthalmitis (a presumed or proven infection of the 
vitreous) and intraocular inﬂ  ammation were reported in 1.3 and 
1.7% of ranibizumab subjects, respectively. No difference in 
systemic hypertension was found between treatment and con-
trol groups, although a slightly higher rate of thromboembolic 
events was found in the 500μg and 300μg groups compared 
with controls (4.6 vs 4.6 vs 3.8%).
The ANCHOR (Anti-VEGF antibody for the treatment of Pre-
dominantly Classic Choroidal Neovascularization in AMD) Trial 
prospectively randomized 423 patients 1:1:1 to receive monthly 
intravitreal ranibizumab (300μg or 500μg) or PDT every 3 months 
as indicated for 24 months. Patients in the ranibizumab group 
were also eligible to receive PDT every 3 months if they showed 
evidence of angiographic leakage from CNV. At inclusion, 
subjects had ﬂ  uorescein angiographic evidence of subfoveal 
predominantly classic CNV secondary to AMD and no prior 
history of PDT treatment.
At 12 months, approximately 95% of subjects in the ranibi-
zumab group maintained or improved vision compared with 
64% of those treated with PDT alone. On average, subjects in 
the 300μg and 500μg ranibizumab groups gained 8.5 and 11 
letters of visual acuity, respectively, compared with a loss of 
9.5 letters in the PDT group (Figure 8).
Adverse events were uncommon, with less than 1% 
of subjects in each group experiencing endophthalmitis, 
intraocular inﬂ  ammation, or cerebrovascular events. The 
frequency of myocardial infarction was slightly higher in 
the 500μg ranibizumab group than in the other two groups 
(2.1 vs 0.7%).
The PIER trial (Phase IIIb, Multicenter, Randomized, 
Double-Masked, Sham Injection-Controlled Study of the 
Figure 4 Disciform scarring of right eye. This end-stage of choroidal neovascularization is represented subretinal ﬁ  brosis and photoreceptor loss.Clinical Interventions in Aging 2006:1(4) 458
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Efficacy and Safety of Ranibizumab) has enrolled 184 
neovascular AMD patients with or without classic CNV to 
receive intravitreal ranibizumab once per month for the ﬁ  rst 
three months followed thereafter by doses once every three 
months for a total of 24 months, with the goal of determin-
ing whether less frequent subsequent dosing will maintain 
treatment efﬁ  cacy. 
At 12 months, 83 and 90% of subjects receiving 300μg 
and 500μg of ranibizumab maintained or improved vision 
compared with 49% of those in the control group (p < 0.0001). 
Unlike MARINA and ANCHOR, subjects treated with this 
lower frequency subsequent dosing of ranibizumab lost 
approximately 1 letter of visual acuity on average. Control 
patients, however, lost 16.3 letters at 12 months (Figure 9). 
No cases of endophthalmitis, uveitis, or thromboembolic 
events were encountered in this small group of subjects. Rates 
of hypertension were similar between all groups.
A smaller phase I/II study, FOCUS (RhuFab V2 
Ocular Treatment Combining the Use of Visudyne to 
Evaluate Safety), studied the efﬁ  cacy of monthly intravitreal 
ranibizumab (500μg) in combination with PDT compared 
with PDT only in 162 patients with predominantly classic 
CNV (Heier et al 2006). At 12 months, approximately 90% 
of subjects in the ranibizumab plus PDT group maintained or 
improved vision compared with 68% in the PDT-only group. 
24% in the combination group and 5% in the PDT-only group 
gained at least 15 letters of vision. On average, those in the 
combination group gained 5 letters of vision, compared with a 
loss of 8 letters of vision in the PDT-only group (Figure 10). 
Interestingly, subjects in the combination treatment group did 
not have improved outcomes when compared with similar 
subjects treated with ranibizumab alone in the ANCHOR 
study. Whether combination treatment will reduce the total 
number of intravitreal and/or PDT treatments required overall 
has not yet been studied.
Another small, open-label phase I/II study, PrONTO 
(Prospective OCT Imaging of Patients with Neovascular 
AMD with Intra-Ocular Lucentis), has studied a variable 
dosing regimen for intravitreal ranibizumab in neovascular 
AMD of any lesion type. A 500μg intravitreal dose was 
given monthly for 3 months to 40 subjects. Follow-up was 
conducted monthly thereafter and ranibizumab was only 
re-injected if there was evidence of persistence or recurrence 
of CNV. At 12 months, subjects required an average of only 
A
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B
Figure 5 Technique of posterior juxtascleral depot injection involves the introduction of cannula into the subconjunctival/subtenon’s space and subsequent advancement 
behind and adjacent to globe.Clinical Interventions in Aging 2006:1(4) 459
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5.5 injections and only 5% of patients required 12 injections 
(ie. needing monthly injections for the entire follow-up pe-
riod) (Rosenfeld 2006). 37.5% of all subjects required only 
3 or 4 injections. Similar to the MARINA and ANCHOR 
studies, subjects gained an average of 9.3 letters. Despite 
a similar average number of injections to the PIER study, 
visual acuity results appear more favourable in PrONTO. 
Although these two protocols have not been directly com-
pared, additional ranibizumab doses at the ﬁ  rst indication 
of CNV persistence/recurrence may be responsible for the 
improved outcomes.
Although visual acuity was the most important outcome 
measured in each of the above studies, signiﬁ  cant anatomic 
resolution of intraretinal, subretinal, and sub-RPE ﬂ  uid has 
been seen with intravitreal ranibizumab. As demonstrated 
by optical coherence tomography (OCT), resolution of ﬂ  uid 
may occur soon after the initial dose and is crucial for visual 
improvement (Figure 11).
It is important to note that intravitreal ranibizumab is the 
ﬁ  rst treatment for neovascular AMD to demonstrate an improve-
ment in visual acuity and that this effect has been repeatedly 
shown in multiple randomized, controlled clinical trials. 
Bevacizumab
Owing to the preliminary results above and the published 
data regarding pegaptanib, enthusiasm has been generated 
for targeted anti-VEGF therapy. As bevacizumab (Avastin) 
is an approved, commercially available, and structurally and 
functionally similar compound to ranibizumab (albeit whole 
antibody compared to an antibody fragment), several early 
studies on its use in neovascular AMD have been published.
In the ﬁ  rst report of SANA (Systemic Avastin for Neo-
vascular AMD), an open-label, uncontrolled study, 9 patients 
with subfoveal CNV secondary to AMD were treated with 
2 to 3 doses of intravenous bevacizumab (5mg/kg) every 2 
weeks and re-evaluated at 12 weeks (Michels et al 2005). 
Patients enrolled had either persistent CNV despite PDT or 
CNV unsuitable for PDT. The authors hypothesized that sys-
temic bevacizumab could be effective by gaining access to the 
subretinal and sub-RPE space by leaking from the CNV and 
binding to extracellular VEGF. Subjects experienced a mean 
12 letter increase in visual acuity, a mean 177μm reduction in 
central retinal thickness, and reduction or absence of angi-
ographic leakage was found in all. No serious systemic or 
Figure 6a Preparation of the eye for an intravitreal injection involves exposure of 
eye with speculum following administration of topical anesthetic drops. Additional 
anesthesia is then given by a topical (anesthetic gel or drop-soaked pledget) or 
subconjunctival route.
Figure 6b Povidone-iodine is applied to ocular surface for sterile preparation. 
Figure 6c The injection site 3–4 mm posterior to limbus is marked using the end 
of a TB syringe. This ensures that the injection will be given through the pars plana. 
An injection given more anterior may result in hemorrhage due to trauma to the 
highly vascularized pars plicata. An injection given more posterior may result in 
retinal detachment.Clinical Interventions in Aging 2006:1(4) 460
Eng and Kertes
ocular side effects were encountered although there was a 
mild, transient elevation in systolic blood pressure. Ongoing 
patient enrollment and longer term follow-up continue.
As intravenous bevacizumab has been associated with 
serious systemic side-effects (to be further discussed below), 
intravitreal bevacizumab has been offered as a treatment for 
CNV. The reduced dose (and therefore cost) of medication 
required may also be considered an advantage over systemic 
administration.
The ﬁ  rst report of intravitreal bevacizumab involved a 
patient with persistent CNV despite PDT and pegaptanib 
treatments. 1.0mg of intravitreal bevacizumab was given 
and resulted in stabilization of visual acuity and resolution 
in subretinal ﬂ  uid and angiographic leakage at 4 weeks 
after treatment (Rosenfeld, Moshfeghi, et al 2005). 
Despite previous studies showing only limited inner retinal 
penetration of whole antibody through the inner retina in 
monkeys Mordenti et al 1999), the authors hypothesized 
that intravitreal administration of bevacizumab might be 
effective because: the aged or diseased human retina may 
allow penetration differently than the nonhuman primate 
model studied; limited retinal penetration of full-length 
antibody or inhibition of vitreous VEGF may be sufﬁ  cient 
to result in a clinically therapeutic effect; or that bevaci-
zumab may penetrate the retina differently than the whole 
antibody used in the primate model.
Figure 6d Intravitreal injection given with a 27- or 30-gauge needle through the 
pars plana.
Figure 7 MARINA 2 year visual acuity results (Genentech, South San Francisco, CA).
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Consistent with the above observation, a recent study has 
shown that intravitreal bevacizumab may pass to all layers 
of the rabbit neurosensory retina, though absent in the RPE 
and choroid, within 24 hours of administration (Shahar 
et al 2006). Bevacizumab was present at 7 days following 
administration but absent at 4 weeks. Further, the 2.5 mg/
0.1 mL bevacizumab dose did not produce any differences in 
full-ﬁ  eld electroretinography (ERG) or ﬂ  ash visual evoked 
potentials at 4 weeks compared with control eyes in the same 
animal receiving intravitreal injections of saline. Although 
a direct correlation between rabbit and human retina cannot 
be made, the retinal toxicity of intravitreal bevacizumab in 
the milligram range is unlikely given the smaller vitreous 
volume of the rabbit eye compared with human (<2 ml vs 
5 mL) and the relatively large dose used in this study (and 
hence a much higher effective concentration of drug).
In a similar study of rabbit eyes, intravitreal bevacizumab 
doses of 0.5 mg to 5.0 mg produced no reduction in ERG am-
plitudes at 2 weeks following administration compared with 
control eyes injected with saline (Manzano et al 2006). There 
was no histologic evidence of retinal toxicity although one 
of three eyes receiving the 5mg dose had some inﬂ  ammatory 
cells in the vitreous. Studies examining the toxic effects of 
serial injections have yet to be conducted.
Electrophysiologic responses to intravitreal bevacizumab 
in humans with neovascular AMD have also been reported 
(Maturi et al 2006). 5 patients underwent full-ﬁ  eld ERG 
testing to evaluate for generalized toxic effects to the retina 
and 4 patients underwent multifocal ERG testing to evaluate 
changes in macular function following intravitreal injection 
of 1.25 mg of bevacizumab. No signiﬁ  cant change in either 
ERG modality was noted at 1 month. However, improve-
ments in macular function may have been blunted by the 
inclusion of patients with recurrent/persistent CNV following 
PDT, pegaptanib, or focal laser treatments only. All subjects 
had stable or improved visual acuity and 75% had reduced 
central macular thickness at 1 month.
Larger retrospective case series have also been reported 
in patients with neovascular AMD. 81 eyes of 79 patients 
received monthly intravitreal bevacizumab (1.25 mg/
0.05 cc) injections, with 37% and 49% experiencing complete 
resolution of retinal edema, subretinal ﬂ  uid, and pigment 
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Figure 8 ANCHOR 1 year visual acuity results (Genentech, South San Francisco, CA).Clinical Interventions in Aging 2006:1(4) 462
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epithelial detachment at 4 and 8 weeks, respectively (Avery 
et al 2006). Median visual acuity improved from 20/200 to 
20/80 at both 4 and 8 weeks. Of note, 78% of patients had 
previously failed treatment with PDT and/or pegaptanib. No 
ocular or systemic side effects were reported in this short-
term study.
Another short-term, retrospective study of 266 eyes of 
266 patients receiving monthly intravitreal bevacizumab for 
neovascular AMD found an improvement in mean visual 
acuity from 20/184 to 20/109 at 3 months (Spaide et al 
2006). Mean central macular thickness decreased from 
340μm to 247μm over the same period. 69.7% of patients 
had been previously treated with either PDT, pegaptanib, 
anecortave acetate, or intravitreal triamcinolone. No serious 
ocular side effects were reported. 2 patients each developed 
a myocardial infarction and transient ischemic attack, with 
2 of the 4 having a previous history or signiﬁ  cant risk factors 
for these conditions.
Given its abilities to inhibit angiogenesis and to reduce 
vascular permeability, applications in other ocular conditions 
have been suggested for intravitreal bevacizumab. Its use in 
proliferative diabetic retinopathy (Avery 2006; Spaide and 
Fisher 2006), macular edema secondary to central retinal vein 
occlusion (Rosenfeld, Fung, et al 2005; Iturralde et al 2006), 
pseudophakic cystoid macular edema (Mason et al 2006), and 
neovascular glaucoma (Davidorf et al 2006) has been reported 
in small case series, with regression of neovascularization or 
reduction in macular edema noted in all cases.
Potential complications
Complications from intraocular treatment may generally be 
classiﬁ  ed into those related to the mode of drug delivery (ie, 
the intravitreal injection) or those related to the drug itself. 
Over a 1 year study period involving 890 eyes, each receiving 
9 intravitreal injections of pegaptanib: 1.3% of patients devel-
oped endophthalmitis, 0.6% developed a traumatic injury to 
the crystalline lens, and 0.7% developed a retinal detachment 
(Gragoudas et al 2004). Although the per injection rate of each 
of these serious adverse events is low, their importance should 
not be minimized considering the cumulative risk over a long 
treatment period and the increased frequency of ranibizumab 
dosing (ie, 4 weeks vs 6 weeks for pegaptanib). Data from 
Figure 9 PIER 1 year visual acuity results (Genentech, South San Francisco, CA). 
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Figure 10 FOCUS 1 year visual acuity results (Genentech, South San Francisco, CA).
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the MARINA and ANCHOR ranibizumab studies conﬁ  rm 
similar rates of endophthalmitis and raise concern. Studies 
examining potential injection-related complications over a 
longer follow-up period have yet to be performed but will be 
important in assessing the overall safety of serial intraocular 
injections given over a lengthy treatment period.
Systemic intravenous administration of bevacizumab has 
been shown to increase the risk of hypertension (p < 0.01) in 
patients being treated for metastatic colorectal cancer (Hurwitz 
et al 2004). Doses used were the same as those used to treat 
CNV in the SANA study (5 mg/kg). Though rates of leukope-
nia, diarrhea, proteinuria, and thrombotic events were slightly 
higher in the bevacizumab group compared with controls, the 
difference did not reach statistical signiﬁ  cance. 
In a study of intravenous bevacizumab for the treatment 
of metastatic renal cell cancer, there was a statistically 
signiﬁ  cant increased rate of epistaxis, hypertension, hema-
turia, and proteinuria in patients treated with bevacizumab 
compared with controls (Yang et al 2003). However, these 
adverse events were only encountered in the “high dose” 
(10 mg/kg) dose and not in the “low dose” (3 mg/kg) be-
vacizumab treatment group.
Though it is reassuring that mortality, hypertensive disor-
ders, hemorrhagic, and thromboembolic event rates were not 
different between patients receiving intravitreal pegaptanib 
compared with placebo over 54 weeks (Gragoudas et al 
2004), this follow-up period is relatively short and many 
patients may require continued treatment. Further, systemic 
side effects of ranibizumab may be different given its ability 
to inhibit all isoforms of VEGF.
Despite nonstatistically signiﬁ  cant results, intravitreal 
ranibizumab data indicate a trend towards higher rates of 
cerebrovascular  events  and  myocardial  infarction com-
pared with controls in the MARINA and ANCHOR trials, 
although statistical signiﬁ  cance and ﬁ  nal data are still to 
be provided.
Although systemic ranibizumab concentrations are ex-
tremely low following intravitreal injections (Gaudreault 
et al 2005) (especially when compared with intravenous 
administration), the effect of systemic VEGF inhibition 
has yet to be determined. Maximum serum levels of 
ranibizumab following a single intravitreal injection in 
the monkey have been shown to be 150 ng/mL. However, 
serum levels of  VEGF-165 in normal humans have been 
found to be only 159.7 pg/mL (with a 2 standard devia-
tion range of 15–500 pg/mL) (Larsson et al 2002). The 
effect of a 1000-fold excess of systemic VEGF inhibition 
is not known although implications on wound healing 
and normal homeostatic processes must be considered. 
The short-term safety of VEGF inhibitors appears to Clinical Interventions in Aging 2006:1(4) 464
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be validated by the studies discussed above. However, 
long-term effects are yet to be determined.
Future directions
Whether a combination of treatments will be more effective 
than a single modality in preserving vision in patients with 
neovascular AMD remains to be proven. However, it would 
seem intuitive that treatments of differing mechanisms of 
action targeting different stages and structures of CNV patho-
genesis should result in more favorable outcomes. Given the 
varying mechanisms, intensity, and cost of different therapies, 
it is conceivable that future combinations will employ some 
modalities in the acute exudative phase of CNV (eg, VEGF 
inhibitors, PDT) and others in the chronic, convalescent phase 
(eg, anecortave acetate, corticosteroids). Determining the best 
sequence and combination of modalities to employ remains a 
challenge for the future.
Selection of combination treatment will only become more 
complex as further treatments are developed. Promising thera-
pies in development include: other VEGF inhibitors; VEGF 
traps; small interfering RNA (siRNA) to block translation/pro-
duction of VEGF or its receptor; pigment epithelium-derived 
factors (PEDF) to counterbalance the angiogenic effects of 
VEGF; and tyrosine kinase inhibitors to block signal transduc-
tion following VEGFR binding. 
Summary
Many different therapies for neovascular AMD have become 
available in the last 10 years. In addition to focal thermal 
laser, ophthalmologists have had photodynamic therapy and 
intravitreal pegaptanib to treat CNV. Both corticosteroid 
and anecortave acetate may prove to be useful adjuncts to 
the above, but require more evaluation. With recent FDA-
approval of ranibizumab and bevacizumab showing great 
Figure11a  OCT of neovascular AMD pre-ranibizumab treatment, visual acuity 20/100. Note intra- and sub-retinal ﬂ  uid and macular thickening.
Abbreviations:  AMD, age-related macular degeneration; OCT, optical computed tomography.
Figure11b  OCT of neovascular AMD 1-week post-ranibizumab treatment, visual acuity 20/40. Note signiﬁ  cant resolution of intra- and sub-retinal ﬂ  uid, reduction in macu-
lar thickness, and return of foveal contour.
Abbreviations:  AMD, age-related macular degeneration; OCT, optical computed tomography.Clinical Interventions in Aging 2006:1(4) 465
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promise, it appears that there are now even greater treatment 
options for this visually devastating condition. It is particu-
larly noteworthy that these compounds appear, for the ﬁ  rst 
time, to provide a treatment for neovascular AMD producing 
signiﬁ  cant improvements in visual acuity. However, enthu-
siasm must be tempered by concerns about long term safety, 
both ocular and systemic. 
Optimal management of neovascular AMD remains elu-
sive and further studies will be required to determine whether 
emerging therapies will prove to be effective and whether a 
combination of treatments offers a better overall visual result 
than any one therapy alone.
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